Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05125939 · ClinicalTrials.gov registry record

Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study

A clinical trial of Colonoscopy and Adenoma Detection Rate, sponsored by Evergreen General Hospital, Taiwan.

Recruiting
Registry status
2,700
Enrollment target
6
Study locations

NCT05125939 is a study of Colonoscopy and Adenoma Detection Rate that is actively recruiting participants, run by Evergreen General Hospital, Taiwan. The registered enrollment target is 2,700 participants, above the 367-participant average among 20 other Colonoscopy trials with a reported enrollment target (636% higher). The trial reports 6 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05125939, a study of Colonoscopy and Adenoma Detection Rate, is actively recruiting participants, sponsored by Evergreen General Hospital, Taiwan.

RECRUITING
Registry status
2,700 participants
Enrollment target
6
Study locations

Study Summary

This is a prospective equivalence colonoscopy study evaluating whether overall adenoma detection rate (ADR) is a reliable alternate for screening ADR. Overall indication includes screening, surveillance, and diagnostic indications.

Interventions

  • OTHER Comparison of ADR

Study Locations (6)

Other

  • E-Da Dachang Hospital - Kaohsiung City
  • E-Da Hospital - Kaohsiung City
  • Keelung Chang Gung Memorial Hospital - Keelung
  • Evergreen General Hospital - Taoyuan District
  • Linkou Chang Gung Memorial Hospital - Taoyuan District

California

  • Sepulveda Ambulatory Care Center, VAGLAHS - North Hills

Trial Details

FieldValue
Enrollment Target 2,700 participants
Start Date 2021-11-20
Est. Completion 2026-09-30

What the Registry Record Tells You About NCT05125939

The ClinicalTrials.gov registry entry for NCT05125939 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,700 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 367-participant average among 20 other Colonoscopy trials with a reported enrollment target (636% higher). The listed sponsor is Evergreen General Hospital, Taiwan, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Colonoscopy appearing as the primary indexed condition, and to 1 intervention - of which Comparison of ADR is the first listed.

NCT05125939 reports 6 study locations spanning 2 distinct geographic areas - top geographies include Other, California.

Frequently Asked Questions

What is clinical trial NCT05125939 about?

NCT05125939 is a clinical study titled "Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study". This is a prospective equivalence colonoscopy study evaluating whether overall adenoma detection rate (ADR) is a reliable alternate for screening ADR. Overall indication includes screening, surveillance, and diagnostic indications.

What is the current status of trial NCT05125939?

This trial is currently recruiting. The enrollment target is 2,700 participants. The study started on 2021-11-20. Estimated completion is 2026-09-30.

What conditions does trial NCT05125939 study?

This clinical trial studies the following conditions: Colonoscopy, Adenoma Detection Rate.

What interventions are being tested in trial NCT05125939?

The interventions under investigation include: Comparison of ADR (OTHER).

Who is sponsoring clinical trial NCT05125939?

This trial is sponsored by Evergreen General Hospital, Taiwan, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05125939 being conducted?

This trial has 6 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colonoscopy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.